

12 1¹

100%)

API

(A) (B)

2

2 () A B () A B 2

Food and Drug Administration (2002). *Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products – General considerations*. Rockville, MD: Food and Drug Administration. Retrieved 23 June, 2015, from <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalPr>

ocess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154838.pdf

- Wang, H. □ Li, Q. □ Reyes, S. □ Zhang, J. □ Xie, L. □ Melendez, V. □ Hickman, M. □ Kozar, M.P. (2013). Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity. *Malaria Research and Treatment*, Retrieved June 23, 2015, from <http://dx.doi.org/10.1155/2013/769234>
- Johnson, J.A. (2000). Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. *International Journal of Clinical Pharmacology and Therapeutics* □38□53-60□

□□□□

1. Tatum, R.P., Shi, G., Manka, M.A., Brasseur, J.G., Joehl, R.J. and Kahrilas, P.J. (2000). Bolus transit assessed by an esophageal stress test in postfundoplication dysphagia. *Journal of Surgical Research*, 91, 56–60.
2. MobiSystems, Inc. (2007). *Dorland's Medical Dictionary for Health Consumers*. [Mobile application software].

□□□□